ArticleFrontiers in oncology2026
Using gene methylation detection in bronchoscopic samples combined with morphology-based pathology for lung cancer diagnosis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is a common malignant tumor with high incidence and mortality. Bronchoscopy is key for its diagnosis, but traditional morphology-based pathology has limitations like missed diagnoses. This study explored the auxiliary diagnostic value of gene methylation detection combined with morphology-based pathology in bronchoscopic samples. Methods: A retrospective analysis was conducted on 654 patients who underwent bronchoscopy at Zhangjiakou First Hospital between March 2023 and May 2024. The cohort included 571 alveolar lavage fluid samples and 83 transbronchial needle aspiration (TBNA) samples. Methylation-specific PCR (MS-PCR) was employed to detect the methylation status of the SHOX2 and RASSF1A genes in these samples. The diagnostic value was evaluated by comparing the results with the final clinical diagnosis. Results: For alveolar lavage fluid samples, the sensitivity of combined SHOX2 and RASSF1A methylation detection reached 94.1%, which was significantly higher than the 30.0% sensitivity of morphology-based pathology (P < 0.001). For TBNA needle tract washing fluid samples, the sensitivity of combined methylation detection was 94.8%, higher than the 86.2% sensitivity of morphology-based pathology, though the difference was not statistically significant (P = 0.075). When gene methylation detection was combined with morphology-based pathology, the area under the curve (AUC) values were 0.9431 for alveolar lavage fluid samples and 0.9828 for TBNA samples, indicating favorable diagnostic performance. Additionally, strong positive results from methylation detection exhibited a high positive predictive value for lung cancer. Discussion: Gene methylation detection in alveolar lavage fluid and TBNA needle tract washing fluid, when combined with morphology-based pathology, can enhance the diagnostic efficiency of lung cancer and is worthy of further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.